<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13362">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02932969</url>
  </required_header>
  <id_info>
    <org_study_id>CV013-018</org_study_id>
    <nct_id>NCT02932969</nct_id>
  </id_info>
  <brief_title>Study With Healthy Japanese and Non-Asian Participants With BMS-986231</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-controlled, Single Continuous Intravenous Infusion Study of BMS-986231 to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Japanese and Non- Asian Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase 1 study is to evaluate the safety, tolerability, PK, and
      pharmacodynamics (PD) of BMS-986231 in healthy Japanese and Non-Asian participants. There is
      no formal hypothesis to be statistically tested.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2016</start_date>
  <completion_date type="Anticipated">April 15, 2017</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single continuous IV infusion of BMS-986231 in healthy Japanese and Non-Asian participants based on Adverse events, clinical laboratory values, vital signs, ECGs, and physical examinations</measure>
    <time_frame>11 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Heart Decompensation, Acute</condition>
  <arm_group>
    <arm_group_label>Panel 1 Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986231 and BMS-986231 Placebo intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 2 Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986231 and BMS-986231 Placebo intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 3 Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986231 and BMS-986231 Placebo intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986231</intervention_name>
    <arm_group_label>Panel 1 Arm</arm_group_label>
    <arm_group_label>Panel 2 Arm</arm_group_label>
    <arm_group_label>Panel 3 Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986231 Placebo</intervention_name>
    <arm_group_label>Panel 1 Arm</arm_group_label>
    <arm_group_label>Panel 2 Arm</arm_group_label>
    <arm_group_label>Panel 3 Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ancestry

               -  First generation Japanese

               -  Non-Asian with grandparents and parents of non-Asian descent

          -  Body weight greater than or equal to 45kg and less than or equal to 110kg

          -  Women of childbearing potential have specific birthcontrol methods

          -  Males sexually active with women of childbearing potential have specific birthcontrol
             methods

        Exclusion Criteria:

          -  History of chronic illness

          -  Chronic headaches

          -  Recurrent dizziness

          -  Personal or family history of heart disease

          -  Personal history of bleeding diathesis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West Coast Clinical Trials, Llc</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Apinya Bee Vutikullird, Site 001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/pages/home.aspx</url>
    <description>BMS Clinical Trial Education Resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/pages/investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 30, 2017</lastchanged_date>
  <firstreceived_date>October 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
